Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021
Tanner E. Rothstein, Scott A. Cunningham, Rachelle A. Rieke, Jill M. Mainella, Melissa M. Mutchler, Robin Patel
Abstract
in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.
Topics & Concepts
Mycoplasma pneumoniaeMicrobiologyVirologyResistance (ecology)BiologyMedicineInternal medicinePneumoniaEcologyPneumonia and Respiratory InfectionsMicrobial infections and disease researchBacterial Infections and Vaccines